JAMA ivermectin study deceived participants on study drug

JAMA ivermectin study deceived participants on study drug

The article “Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19” was published in the Journal of the American Medical Association on March 4. The study subjects were deceived. They were told that the study drug was “D11AX22 Molecule”.

The lead author on the article, Eduardo López-Medina, confirmed that in a telephone conversation. He explained that it would have been difficult to recruit subjects to the study if they were told the study drug was ivermectin. López-Medina stated that this practice was disclosed during ethics and governmental reviews of the study protocol and that it had been approved.

It had been reported earlier that the title of the study protocol used the term “D11AX22 Molecule” instead of “ivermectin”. That raised the question of whether the study subjects had been informed that the study involved ivermectin.

This is a moment that requires moral clarity. The JAMA article needs to be retracted immediately.

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.
...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee